iShares Barclays Aggregate Bond Fund  

(Public, NYSEARCA:AGG)   Watch this stock  
Find more results for agg
110.39
Dec 17 - Close
NYSEARCA real-time data - Disclaimer
Currency in USD
Range 110.39 - 110.39
52 week 105.35 - 112.08
Open 110.39
Vol. 0.00
Mkt cap 22.08B
P/E 20.18
Div/yield 0.19/2.16
EPS 5.47
Shares 199.80M
Beta -0.06
Inst. own 55%

Key stats and ratios

Q3 (Aug '14) 2014
Net profit margin 239.66% -2.65%
Operating margin 96.74% 96.65%
EBITD margin - 96.65%
Return on average assets 3.93% -0.05%
Return on average equity 5.50% -0.06%
CDP Score - -

Address

45 Fremont Street
San Francisco, 94105
United States - Map
+1-800-4742737 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

iShares Core Total US Bond Market ETF, formerly iShares Barclays Aggregate Bond Fund (the Fund) seeks investment results that correspond generally to the price and yield performance, of the total United States investment grade bond market as defined by the Barclays Capital U.S. Aggregate Bond Index (the Index). The Index provides a measure of the performance of the United States investment grade bonds market, which includes investment grade the United States Government bonds, investment grade corporate bonds, mortgage pass-through securities and asset-backed securities that are publicly offered for sale in the United States. The securities in the Index must have at least one year remaining to maturity. The Fund generally seeks to track the performance of the Index by investing approximately 90% of its assets in the bonds represented in the Index and in securities that provide substantially similar exposure to securities in the Index.

Officers and directors

Joseph Kippels Portfolio Manager of the Manager
Bio & Compensation  - Reuters
Chris Mosellen Portfolio Manager of the Manager
Bio & Compensation  - Reuters
Lee Sterne Senior Portfolio Manager of the Manager
Age: 48
Bio & Compensation  - Reuters
John Sulski Portfolio Manager of the Manager
Bio & Compensation  - Reuters